This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Vaccinating with TicoVac and TicoVac JuniorSupport & ResourcesSupport & ResourcesVideosMaterials
Click here for TicoVac (Tick - Borne Encephalitis Vaccine (whole Virus, inactivated)) Prescribing Information. Adverse event reporting information can be found at the bottom of the page. 
TicoVac® (Tick-Borne Encephalitis Vaccine (whole Virus, inactivated))

Without any specific treatment for TBE, prevention is key.1 Vaccination is a recommended and proven way to help protect against tick-borne encephalitis (TBE) and should be considered for all travellers at risk.2,3

Click here for information to help identify who is at risk

TicoVac® and TicoVac® Junior are vaccines that have been proven to prevent 99% of cases of TBE in vaccinated populations.​1,2

TICOVAC AND TICOVAC JUNIOR OFFER A CHOICE OF SCHEDULES TO SUIT TRAVEL TIMELINES4,5

In cases where protection is needed quickly, the rapid immunisation schedule can be used; for optimal coverage always complete the vaccination schedule.4,5

  • TicoVac (0.5 ml) is suitable for adults aged 16 years and older.4​​​​​​​
  • TicoVac Junior (0.25 ml) is suitable for children aged from 1 year to 15 years.5

 

Supporting resources​

To help you to identify those at risk of TBE and support your travel health consultations about TBE with people at risk, we have a series of eModules and knowledge check worksheets available to you on PfizerPro. ​

Watch this short video to learn about these resources....

You can find these resources by clicking hereLoading

References

Lindquist L. and Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-71Rendi-Wagner P. Risk and prevention of tick-borne encephalitis in travellers. J Travel Med. 2004;11:307–312 WHO. Health Topics: Tick-borne encephalitis prevention. Available at: https://www.who.int/health-topics/tick-borne-encephalitis#tab=tab_3 (Last accessed: May 2023)TicoVac Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/1923 (Last accessed: May 2023)TicoVac Junior Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/1927 (Last accessed: May 2023)
Frequently Asked Questions
Loading
Frequently Asked Questions


Who is TicoVac® indicated for?​

TicoVac® (0.5 ml) is indicated for the active (prophylactic) immunisation of persons 16 years of age and older against tick-borne encephalitis (TBE).​4

TicoVac® Junior (0.25 ml) is indicated for the active (prophylactic) immunisation of ​

children aged from 1 to 15 years against TBE.​5

What if I have a patient who is travelling to a TBE risk area in a month?​

If you are unable to follow the conventional vaccination schedule, you may follow the rapid schedule, which can offer sufficient protection against TBE virus infection as early as 14 days after the second dose.4,5 ​

In the rapid immunisation schedule, the first and second doses should be given 14 days apart and the third dose 5-12 months after the second.​4,5

In both schedules, the first booster is given 3 years after the third dose of the primary vaccination.4,5

Why is a third dose recommended as part of the primary vaccination course?​

A third dose of TicoVac® is needed for longer protection.​4,5

What happens if the vaccinee misses their third dose or one of their booster doses?​

TicoVac® offers a single catch-up dose for those who have missed a scheduled vaccine dose but have received at least two doses of the TBE vaccine. Following a catch-up dose, people can continue with the booster vaccination schedule.4,5

It is important to remember that in the period between a missed scheduled dose and the catch-up dose, protection against TBE by TicoVac® may not be maintained.​4,5

Tick-Borne Encephalitis (TBE)

Understand how ticks carry TBE, the endemic areas and advice for prevention of infection.

Explore TBELoading
PP-TCV-GBR-0153. May 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​